RESUMEN
In the present manuscript we present evidence of the improvement of MASLD with dietary intervention. It is known that the Mediterranean diet is the best intervention for this pathology, however, it cannot be established in all countries due to the diversity of foods. We create a Mexican diet with the nutrients of the Mediterranean diet for the treatment of our population.
RESUMEN
OBJECTIVE: To describe the characteristics of the body components and phase angle (PhA) of patients with MAFLD according to those different to fibrosis and hepatic steatosis. MATERIAL AND METHODS: Observational and descriptive study in a cohort of 585 volunteers from our center with MAFLD criteria. The risk of liver fibrosis was determined by APRI, NAFLD score and FIB-4; at an indeterminate and high risk of fibrosis, a transient elastography (Fibroscan®) were realized. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included. RESULTS: 125 participants (21.4%) were evaluated, age 53.9±13.9 years, 62.1% women, BMI 33.2±5.8kg/m2. The SECA® analysis showed mean fat mass of 42%±7.32 and muscle mass 21.18kg±6.6. The PhA was 5.1±0.69, in women 4.92±0.62 and men 5.41±0.70. PhA in patients without fibrosis was 5.091 vs with fibrosis 5.121 (P=.813). In advanced fibrosis, it reported a low value compared to the rest of the groups (P=.031). The PhA in S3 was higher compared to S1 and S2 (5.3 vs 4.82, 4.81) (P=.027). CONCLUSIONS: In MAFLD, the PhA was lower than the healthy Mexican population. In patients without fibrosis and severe steatosis, PhA rises proportionally to the increase in fat mass and BMI and in advanced liver fibrosis, PhA decreases.
Asunto(s)
Diagnóstico por Imagen de Elasticidad , Enfermedad del Hígado Graso no Alcohólico , Adulto , Anciano , Composición Corporal/fisiología , Femenino , Humanos , Cirrosis Hepática , Masculino , Persona de Mediana EdadRESUMEN
Objetivo: Describir las características de la composición corporal y del ángulo de fase (AF) en pacientes con MAFLD de acuerdo con fibrosis y esteatosis hepática. Pacientes y métodos: Estudio transversal, observacional y descriptivo en una cohorte de 585 voluntarios de nuestro centro con criterios de MAFLD. El riesgo de fibrosis hepática se determinó por APRI, NAFLD score y FIB-4; en riesgo indeterminado y elevado de fibrosis se realizó elastografía hepática de transición (ET) con Fibroscan®. Se realizó análisis de la composición corporal por bioimpedancia (SECA®). Se incluyeron pacientes con registro de ET y SECA®. Resultados: Se evaluaron 125 participantes (21,4%), edad 53,9±13,9 años, 62,1% mujeres, IMC 33,2±5,8kg/m2. El análisis SECA® mostró media de masa grasa de 42%±7,32 y masa muscular de 21,18kg±6,6. El AF fue 5,1±0,69; en mujeres 4,92±0,62 y en hombres 5,41±0,70. El AF en pacientes sin fibrosis fue de 5,091 vs con fibrosis 5,121 (p=0,813). En fibrosis avanzada se reportó valor bajo en comparación con el resto de los grupos (p=0,031). El AF en S3 fue mayor en comparación con S1 y S2 (5,3 vs 4,82, 4,81) (p=0,027). Conclusiones: En MAFLD el AF fue menor vs población sana mexicana. En pacientes sin fibrosis y esteatosis severa el AF se eleva proporcional al incremento de masa grasa e del IMC, y en fibrosis hepática avanzada el AF disminuye.(AU)
Objective: To describe the characteristics of the body components and phase angle (PhA) of patients with MAFLD according to those different to fibrosis and hepatic steatosis. Material and methods: Observational and descriptive study in a cohort of 585 volunteers from our center with MAFLD criteria. The risk of liver fibrosis was determined by APRI, NAFLD score and FIB-4; at an indeterminate and high risk of fibrosis, a transient elastography (Fibroscan®) were realized. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included. Bioimpedance body composition analysis (SECA®) was performed. Patients with ET and SECA® registry were included. Results: 125 participants (21.4%) were evaluated, age 53.9±13.9 years, 62.1% women, BMI 33.2±5.8kg/m2. The SECA® analysis showed mean fat mass of 42%±7.32 and muscle mass 21.18kg±6.6. The PhA was 5.1±0.69, in women 4.92±0.62 and men 5.41±0.70. PhA in patients without fibrosis was 5.091 vs with fibrosis 5.121 (P=.813). In advanced fibrosis, it reported a low value compared to the rest of the groups (P=.031). The PhA in S3 was higher compared to S1 and S2 (5.3 vs 4.82, 4.81) (P=.027). Conclusions: In MAFLD, the PhA was lower than the healthy Mexican population. In patients without fibrosis and severe steatosis, PhA rises proportionally to the increase in fat mass and BMI and in advanced liver fibrosis, PhA decreases.(AU)